Inspired by preclinical research indicating that metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates PD-1 blockade, the combination of nivolumab with metformin in MSS mCRC patients did not demonstrate efficacy despite being well tolerated by patients [68]. This evidence concerns the gene PDCD1 and neoplasm.